Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study

European Heart Journal

Volumn 19, Issue 1, 1998, Pages 55-62

  Woodward, M ^a,b   Lowe, G D O ^c   Rumley, A ^c   Tunstall Pedoe, H ^a,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

All causes mortality; Coronary heart disease; Fibrinogen

Indexed keywords

CHOLESTEROL; COTININE; FIBRINOGEN; TOBACCO SMOKE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 0031939624     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0573     Document Type: Article

References (40)

1. [1] Meade TW. Haemostatic function, arterial disease and the prevention of arterial thrombosis. Baillière's Clin Haematol 1994; 7: 733-55.
2. [2] Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
3. [3] Lowe GDO, Fowkes FGR, Koenig W, Mannucci PM, eds. Fibrinogen and cardiovascular disease. Eur Heart J 1995; 16 (Suppl A).
4. [4] Resch KL, Ernst E. The complex impact of fibrinogen on atherosclerosis-related disease. In: Koenig W, Hombach V, Bond MG, Kramsch DM, eds. Progression and regression of atherosclerosis. Vienna: Blackwell MZV, 1995: 36-40.
5. [5] Meade TW, North WRS, Chakrabarti R et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 1050-4.
6. [6] Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Study. Lancet 1986; ii: 533-7.
7. [7] Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
8. [8] Stone MC, Thorp MC. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 1985; 35: 565-9.
9. [9] Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-6.
10. [10] Yarnell JWB, Baker IA, Sweetnam PM et al. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
11. [11] Heinrich J, Balleisen L, Schulte H, Assmann G, van der Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
12. [12] Cremer P, Nagel D, Labrot B et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
13. [13] Clauss A. Gerrinungsphysiologische schnellmethode zur bestimmmung des fibrinogens. Acta Haematol (Basel) 1957; 17: 237-46.
14. [14] Poller L. Quality control in blood coagulation. In: Thompson JM, ed. Blood coagulation and haemostasis: a practical guide, 2nd edn. Edinburgh: Churchill Livingstone, 1980: 330-59.
15. [15] Gaffney PJ, Wong MY. Collaborative study of proposed international standard for plasma fibrinogen measurements. Thromb Haemostas 1992; 68; 428-32.
16. [16] Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-20.
17. [17] Smith WCS, Tunstall-Pedoe H, Crombie IK, Tavendale R. Concomitants of excess coronary deaths: Major risk factor and lifestyle findings from 10 359 men and women in the Scottish Heart Health Study. Scot J Med 1989; 34: 550-5.
18. [18] Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-19.
19. [19] Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-42.
20. [20] Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br H Haematol 1993; 83: 616-21.
21. [21] Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey M-K. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. BMJ 1997; 315: 722-9
22. [22] Smith WCS, Crombie IK, Tavendale R, Irving JM, Kenicer MB, Tunstall-Pedoe HD. The Scottish Heart Health Study: objectives and development of methods. Health Bull (Edin) 1987; 45: 211-17.
23. [23] Bolton-Smith C, Smith WCS, Woodward M, Tunstall-Pedoe H. Nutrient intakes of different social class groups: Results from the Scottish Heart Health Study. Br J Nutr 1991; 65: 321-35.
24. [24] Bortner KW. A short rating scale as a potential measure of pattern A behaviour. J Chronic Dis 1969; 22; 87-91.
25. [25] Rose GA, McCartney P, Reid DD. Self-administration of questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med 1977; 31; 42-8.
26. [26] Woodward M, Tunstall-Pedoe H, Smith WCS, Tavendale R. Smoking inhalation and blood biochemistry in the Scottish population. J Clin Epidemiol 1991; 44: 1405-10.
27. [27] Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrographic findings. Bristol: John Wright, 1982.
28. [28] WHO MONICA Project, prepared by Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A. Myocardial infarction and coronary deaths in the World Health Organisation MONICA Project - Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in 4 continents. Circulation 1994; 90: 583-612.
29. [29] Anderson B. Methodological errors in medical research. Oxford: Blackwell, 1990.
30. [30] Thompson SG, Kienast J, Pyke SDM, Haverkate F, van der Loo JCW. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
31. [31] Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics of clotting factors and the risk of ischaemic heart disease. Lancet 1987; ii: 986-8.
32. [32] Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study. Am Heart J 1987; 113: 1006-10.
33. [33] Green KG, Heady A, Oliver MF. Blood pressure, cigarette-smoking and heart attack in the WHO Cooperative trial of clofibrate. Int J Epidemiol 1989; 18: 355-60.
34. [34] Oliver MF, Heady JA, Morris JN, Cooper J. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069.
35. [35] Lowe GDO. Risk factors in cardiovascular disease. In: Cleland J, ed. Asymptomatic coronary artery disease and angina. London: Science Press, 1996: 13-27.
36. [36] Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
37. [37] Behague I, Poirier O, Nicaud V et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction - the ECTIM Study. Circulation 1996; 93; 440-9.
38. [38] Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study (LETS). Thromb Haemostas 1994; 71: 719-22.
39. [39] Lowe GDO, Campbell AF, Meek DR, Forbes CD, Prentice CRM, Cummings S. Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur. Lancet 1978; ii: 698-700.
40. [40] Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994; 25: 1755-9.